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Abstract 
Nifurtimox and benznidazole represent the only treatments options available targeting Chagas 
disease, the most important parasitic infection in the Americas. However, use of these is problematic 
as they are toxic and ineffective against the more severe stages of the disease. In this work, we used 
a multidisciplinary approach to characterise the fumarases from Trypanosoma cruzi, the causative 
agent of Chagas Disease. We showed this trypanosome expresses cytosolic and mitochondrial 
fumarases that via an iron-sulfur cluster mediate the reversible conversion of fumarate to S-malate. 
Based on sequence, biochemical properties and co-factor binding, both T. cruzi proteins share 
characteristics with class I fumarases, enzymes found in bacteria and some other protozoa but absent 
from humans, that possess class II isoforms instead. Gene disruption suggested that although the 
cytosolic or mitochondrial fumarase activities are individually dispensable their combined activity is 
essential for parasite viability. Finally, based on the mechanistic differences with the human (host) 
fumarase, we designed and validated a selective inhibitor targeting the parasite enzyme. This study 
showed that T. cruzi fumarases should be exploited as targets for the development of new 
chemotherapeutic interventions against Chagas disease. 
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1. Introduction 
Throughout Latin America approximately 8 million people suffer from Chagas disease, a neglected 
tropical infection caused by the flagellated protozoan parasite Trypanosoma cruzi (World Health 
Organization, 2013). This disease is characterised by a series of life-threatening mega syndromes that 
promote damage to the heart, intestines and central nervous system, severely affecting the quality of 
life of infected patients [1].  
 
The  normal route of transmission of this zoonotic infection is via the hematophagous behaviour of 
insects belonging to the Reduviidae family, in which part of T. cruzi’s life cycle occurs, to humans, 
where the cycle is completed [2]. However, as a result of alternative modes of transmission such as 
through blood transfusions, organ transplantation, congenital and ingestion of contaminated food [3], 
and population migration, Chagas disease has started to emerge as a public health problem at non-
endemic sites such as the USA and Europe [4]. 
 
Benznidazole and nifurtimox currently represent the only treatment options available against Chagas 
disease but their use is controversial. They are highly toxic and not effective in curing the infection 
during the lethal disease staging while some strains are refractory to treatment. In addition, the drug 
regimens are prolonged with a course of treatment requiring multiple daily doses taken over a 1 to 4 
month period. Often, the recommended schedules are not completed, usually because of their side 
effects, resulting in considerable scope for the development of resistance. There is a considerable 
need for novel therapeutic strategies targeting Chagas disease and exploring the biochemistry of T. 
cruzi is seen as an important strategy to identify and validate new drug targets for the development 
of innovative treatments [5]. 
 
Fumarases (EC 4.2.1.2), also known as fumarate hydratases, are ubiquitous enzymes that catalyse 
the reversible conversion of fumarate to L-malate [6]. Based on sequence, structure, biochemical 
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properties and co-factors, they can be divided into three distinct types [7]. Class I fumarases primarily 
expressed by bacteria and some protozoa, are homodimeric iron-sulfur (4Fe-4S) containing enzymes 
of approximately 120 kDa in size, and are readily inactivated by superoxide anions, heat or radiation. 
In contrast, class II fumarases are homotetrameric, iron independent proteins of approximately 200 
kDa in size that are expressed by bacteria and numerous eukaryotes including higher plants, fungi 
and mammals [8]. Higher eukaryotic cells express one class II enzyme that is dual localized by reverse 
translocation after undergoing proteolytic processing to generate different echoforms [9-11]. One of 
these forms is localized to the mitochondrion where it participates in the Kreb’s cycle while the 
second, located in the cytosol, plays a role in amino acid and fumarate metabolism. Intriguingly, the 
cytosolic variant is postulated to participate in the cellular response to DNA double strand breaks 
with this enzyme undergoing transport into the nucleus [12]. A third fumarase class has been 
identified from prokaryotes. This enzyme is composed of a heterodimer with an alpha and a beta 
subunit resembling the N-terminal and C-terminal parts of class I fumarase, respectively [13, 14]. 
 
Analysis of the trypanosomal databases has shown that trypanosomes have the potential to express 
two class I fumarases, enzymes that are completely distinct from the class II counterparts found in 
humans. This, coupled with the observation that the total fumarase activity in an insect-stage 
Trypanosoma brucei cell is essential for parasite viability [15], prompted us to evaluate whether these 
enzymes constitute anti-chagasic drug targets. Here, we show that the total fumarase activity is 
important, if not essential, for T. cruzi viability and that both T. cruzi enzymes catalyse the reversible 
conversion of fumarate to L-malate with this activity being readily inhibited by the sulfur-containing 
malate derivative, thiomalate. Our results suggest that fumarase could be exploited as a potential drug 
target in T. cruzi and thus selective inhibiton of fumarase may constitute a new strategy against 
Chagas disease.   
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2. Materials and Methods  
2.1 Cell culturing  
T. cruzi epimastigote Sylvio X.10.6 were grown at 28°C in RPMI 1640 medium supplemented with 
5 g L-1 trypticase, 20 mM HEPES pH 7.5, 10 % (v/v) heat-inactivated calf fetal serum, 0.22 g L-1 
sodium pyruvate, 0.34 g L-1 sodium glutamate, 2500 U L-1 penicillin, 0.25 g L-1 streptomycin and  20  
mg L-1 hemin. DNA was introduced into T. cruzi epimastigotes using the Human T-cell Nucleofector® 
kit and an Amaxa® Nucleofector™ (Lonza AG) set to program X-001. Transformed parasites were 
grown in the presence of 5 or 10 µg mL-1 puromycin, 5 or 10 µg mL-1 blasticidin, 5 µg mL-1 
hygromycin and/or 100 µg mL-1 G418. 
 
T. cruzi amastigote parasites were grown in African green monkey kidney epithelial (Vero) cells at 
37 °C in a 5% (v/v) CO2 atmosphere in RPMI 1640 medium. Uninfected Vero cells were maintained 
in this medium and sub-cultured following trypsin treatment. To produce T. cruzi metacyclic cells, 
epimastigote cultures were allowed to grow to late stationary phase resulting in differentiation of the 
parasite. These were used to infect Vero cells. Following overnight incubation at 37 °C in a 5% (v/v) 
CO2 atmosphere, non-internalized parasites were removed by washing in liver infusion tryptose 
medium containing non-inactivated fetal calf serum. Bloodstream form metacyclics emerged 10 days 
after the initial infection and used to infect new Vero cells at a ratio of 10 parasites per mammalian 
cell. After 2 days, the medium was aspirated and the cells examined microscopically following 
Giemsa staining. The percentage of infected Vero cells and the number of amastigotes per infected 
cell were determined by analyzing 100 host cells randomly distributed across several fields of view. 
The mean number of parasites found in all host cells (mean abundance) was calculated using the 
quantitative software (QPweb 1.0) with 95% confidence interval by the bias-corrected and accelerated 
(BCa) bootstrap method with 2000 bootstrap replications. 
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2.2 Protein purification 
The vectors used to express various fumarases in E. coli were generated as follows: full length Tcfhc 
was amplified from T. cruzi genomic DNA (gDNA) with the primers 
gaattcATGAGTCTGTGCGAAAACT and gcggccgcATCAAAGGAGTTTGGAAAAAAAG (lower 
case correspond to restriction sites incorporated into the primers to facilitate cloning). The amplicon 
was digested with EcoRI and NotI then cloned into the corresponding sites of the pET-28a vector 
(Novagen). The fumarase gene was subcloned into pET-28a-SUMO [16] using EcoRI and XhoI such 
that a DNA sequence gene coding for a hexahistidine-tagged SUMO was inserted in-frame at the 5’ 
end of the Tcfhc-derived DNA fragment. For TcFHm heterologous expression, the full length Tcfhm 
gene was amplified from T. cruzi gDNA with the primers ggatccATGCTGCGCCGTTCTGC and 
gcggccgcagcaTTGGACTCATTTGAGCTG, the resultant fragment digested with BamHI and NotI, 
and cloned into the corresponding sites in pET-28a-SUMO. The human fumarase gene (Hsfh) was 
subcloned from the pET-28a-HsFH construct [17] into pET-28a-SUMO using BamHI and XhoI 
restriction sites. 
 
Overnight cultures of E. coli BL21 (DE3) harboring a pET-28a-SUMO vector containing the 
fumarase genes were diluted 1:100 in Lysogeny Broth containing 30 µg mL-1 kanamycin and grown 
at 37 oC with aeration until the culture reached the logarithmic phase of growth (OD600nm ~ 0.5-0.6). 
E. coli  cultures were transferred to 18°C for 30 min and protein expression induced by addition of β-
D-thiogalactopyranoside (IPTG) (TcFHc: 5 µM; TcFHm: 50 µM; HsFH: 500 µM). Cultures were 
incubated at 16°C for a further 24 hours before harvesting the cell.  For expression of the T. cruzi 
enzymes, 200 mg L-1 ferrous sulfate heptahydrate, 200 mg L-1 ferric citrate and 2 mM cysteine were 
added to the growth medium. All subsequent purification steps were performed under anaerobic 
conditions. The cells were resuspended in buffer A (50 mM NaH2PO4, pH 8.5, 300 mM NaCl, 10 
mM imidazole) containing 1 mM phenylmethylsulfonyl fluoride then disrupted by sonication using 
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10 x 30 s pulses on ice. The clarified lysate was passed through a Ni-NTA resin (Qiagen) equilibrated 
with buffer A. The resin was washed with the same buffer containing 25 mM imidazole and then re-
equilibrated with buffer A. The histidine tagged protease ULP1 (500 µg) was added to the resin, the 
column incubated overnight at 8 °C. Tag-free enzymes were then eluted off the column with buffer 
A. Enzymes were concentrated and dialyzed against the storage buffer (50 mM Tris pH 8.5, and 150 
mM NaCl) using an ultra-filter unit with 30 kDa cutoff (Amicon-Millipore). 
 
Size exclusion chromatography of TcFHc was carried out using an isocratic run (50 mM Tris pH 8.5, 
600 mM NaCl, 10 mM imidazole and 1 mM DTT)  in a Superdex 200 10/300 (GE Life Sciences). 
The oligomeric state was estimated using molecular weight markers according to the column 
manufacturer’s instructions.  
 
2. 3 Enzyme kinetics 
TcFHc and TcFHm activities were monitored under anaerobic conditions by following the change 
in absorbance at 250 nm due to consumption or formation of fumarate (ε250nm=1.45 mM
-1 cm-1 [18]). 
A reaction mixture containing 50 mM Tris pH 8.5, 150 mM NaCl, fumarate (500, 250, 125, 62.5 and 
31.25 µM) or malate (8, 4, 2, 1, and 0.5 mM) was incubated at 25 °C. The background rate of fumarate 
consumption/formation was determined and the reaction initiated by addition of fumarase (10 µg mL-
1). The protein amount used was corrected based on the iron-sulfur content measured 
spectrophotometrically (ε410nm= 15,000 M
-1cm-1 [19]). Initial reaction rates were plotted versus 
substrate concentration and the Hill model used to fit the data by nonlinear regression in Origin 
(OriginLab, Northampton, MA). 
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2.4 Inhibition studies 
 The effect of thiomalate (Sigma) on the initial reaction rates of TcFHc and HsFH was assessed. 
TcFHc activity in 50 mM Tris pH 8.5, 150 mM NaCl buffer was followed in varying amounts of L-
malate (8, 4, 2, 1, and 0.5 mM) and different thiomalate concentrations (12.86, 4.5, 1.58, 0.55 and 0 
µM). Data were fitted using competitive, non-competitive and uncompetitive models by non-linear 
regression using GraphPad Prism software version 5.00 and the best model was selected based on the 
Akaike information criterion (AICc). For HsFH, activity was monitored in buffer 50 mM Tris pH 8.5, 
150 mM NaCl using 50 mM L-malate with different thiomalate concentrations (200, 100, 50, 25, 12.5 
and 6.25 mM). Activity was expressed as percentage of the maximum activity achieved in absence 
of inhibitor. 
 
Inhibition of TcFHc using different compounds possessing free thiol groups was also tested.  In these 
assays activity was evaluated in buffers containing 50 mM Tris pH 8.5, 150 mM NaCl and 8 mM L-
malate in presence of different concentrations (50 mM, 10 mM, 2 mM, 400 µM, 80 µM, 16 µM, 3.2 
µM, 640 nM and 128 nM) of β-mercaptoethanol (BME), cysteine (Cys), reduced glutathione (GSH), 
dithiotreitol (DTT) and sodium meso-2,3-dimercaptosuccinate (DMSA).  
 
2.5 Electron paramagnetic resonance 
EPR measurements were performed to assess the presence of an iron-sulfur cluster in TcFHc and 
TcFHm. A Bruker Elexsys E580 spectrometer operating at X band (9.5 GHz) equipped with a 
rectangular cavity was utilized. The optimal temperature for the experiments, around that of liquid 
helium (4-10 K), was reached using an Oxford ITC 503 cryostat. The parameters were optimized to 
avoid signal saturation and distortion with the final values: 10 mW microwave potency, 0.2 mT 
magnetic field modulation and 100 kHz magnetic field modulation frequency. Samples contained 87 
µM of protein in a total volume of 50 µL. 
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2.6 Localization studies 
To express an epitope tagged version of TcFHm the corresponding open reading frame minus its 
STOP codon was amplified from T. cruzi gDNA using the primers 
gaattcATGCTGCGCCGTTCTGCGGCA and gatatcTTTGAGCTGTTGGAAGAAGTC. The 
resultant product was digested with EcoRI and EcoRV and cloned into the corresponding site of 
pTEX-Tcntr-9e10 [20], replacing the Tcntr gene. The cloning was carried out such that the DNA 
sequence coding for the c-myc(9e10) epitope was inserted in-frame at the 3’ end of the Tcfhm-derived 
DNA fragment. The construct was then introduced into T. cruzi epimastigotes by electroporation. 
 
T. cruzi harboring pTEX-Tcfhm9e10 were subject to subcellular fractionation following treatment 
with digitonin. Parasites (4 x 109 cells) in logarithmic phase of growth were washed twice and 
resuspended in ice cold buffer D (20 mM Tris-HCl pH 7.2, 225 mM sucrose, 20 mM KCl, 10 mM 
KH2PO4, 1 mM EDTA, 5 mM MgCl) containing protease inhibitor cocktail (Roche). An aliquot of 
cells were lysed with an each volume of 0.2 % (v/v) Triton X-100, 300 mM NaCl and the total protein 
concentration determined using a Pierce BCA Protein Assay Kit (ThermoScientific). The remainder 
of the suspension was diluted such that when lysed a final protein concentration of 3 mg mL-1 was 
achieved. Aliquots of the suspension were mixed with 2 volumes of buffer D containing different 
concentrations of digitonin, incubated for 5 minutes at 28 °C, the samples clarified and supernatants 
collected. Equal volumes of each sample were then SDS-PAGE fractionated and analyzed by western 
blot analysis using antibodies raised against c-Myc(9e10) (Santa Cruz Biotechnology) as TcFHm 
marker and T. brucei enolase, T. brucei aldolase and T. brucei acetyl:succinate CoA transferase as 
cytosol, glycosomal and mitochondrial markers, respectively. A total lysis control sample obtained 
by incubating cells with 0.1 % (v/v) Triton X-100 for 20 min at 4 °C was examined in parallel.  
 
For confocal-based localization studies the Tcfhm and Tcfhc open reading frames minus their STOP 
codons were amplified from T. cruzi gDNA using the primers actagtATGAGT 
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CTGTGCGAAAACTGC and gtcgacAGGAG TTTGGAAAAAAAGTCA (for Tcfhc) or 
actagtATGCTGCGCCGTTCTGCGGCA and gtcgacTTGAGCTGTTGGAAGAAGTCA (for 
Tcfhm). Fragments were digested with SpeI and SalI and cloned into the corresponding sites of pTEX-
eGFP [21]. The cloning was carried out such that the DNA sequence coding for the green fluorescence 
protein (GFP) was inserted in-frame at the 3’ end of the Tcfhm- or Tcfhc-derived DNA fragments. T. 
cruzi epimastigotes expressing TcFHm-GFP (5 x 106 mL-1) were suspended in medium containing 
100 nM Mitotracker® Red CMXRos (Molecular Probes) and incubated at 37°C for 5 min. These cells 
along with parasites expressing TcFHc-GFP were washed twice in PBS, fixed in 2 % (w/v) 
paraformaldehyde/PBS, then washed again in PBS. Aliquots of the cell suspension (105 cells) were 
air-dried onto microscope slides, the parasite genomes stained with 200 pM 4',6-diamidino-2-
phenylindole (DAPI) in 50% glycerol/PBS (Sigma-Aldrich) and slides were viewed by using a Zeiss 
LSM 510 confocal microscope. 
 
2.7 Gene disruption 
The constructs used to disrupt the T. cruzi fumarase genes were generated as follows: Primers were 
designed to amplify 450 or 471 bp fragments from the 5’ and 3’ region of the Tcfhc gene, respectively. 
These were cloned sequentially either side of a puromycin- (pac) or blasticidin- (bla) containing 
resistance cassette. Similarly, primers to designed to amplify 490 and 484 bp DNA fragments from 
the 5’ and 3’ region of the Tcfhm gene, respectively. These were cloned sequentially either side of a 
pac-, bla-, neomycin- (neo) or hygromycin- (hyg) containing resistance cassette. Constructs were 
linearized (SacI/KpnI for the pac, hyg and neo vectors or SacII/KpnI for the bla vector) then 
introduced into T. cruzi epimastigotes by electroporation. Integration of the DNA constructs into the 
T. cruzi genome results in deletion of ~50% of Tcfhc or Tcfhm coding sequence.  
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3. Results 
3.1 Trypanosoma cruzi enzymes display type I fumarase characteristics 
Two ORFs in the T. cruzi genome database [22] were identified as having potential to encode for 62 
kDa proteins related to fumarase enzymes. One 1698 bp sequence (TcCLB.507257.60) located on 
chromosomes 36 was designated as Tcfhc and the second 1668 bp ORF (TcCLB.507669.10) found 
on chromosomes 26 was designated as Tcfhm. The deduced amino acid sequence of the two T. cruzi 
fumarases share 61% identical residues to each other with most of the differences found in their amino 
termini, and shared 75 to 82% identical residues to their T. brucei and Leishmanial orthologues, 
respectively. When TcFHc and TcFHm were compared to fumarases from other organisms they 
exhibited significant identity (~60%) to the class I enzymes from unicellular eukarytotes and bacteria 
and no similarity to the class II fumarases present in higher eukarytotes such as humans. 
 
To facilitate their biochemical characterisation TcFHc and TcFHm were expressed as 6x(His)-
SUMO amino termini tagged proteins in E. coli, affinity purified on a Ni2+ column and eluted off the 
matrix following cleavage with the ULP1 protease, releasing the untagged fumarase (Figure 1A). To 
determine its oligomeric state, purified TcFHc was subjected to size exclusion chromatography, 
eluting off the column as a size peak of ~147 kDa (Figure 1B). This is close to the expected size of a 
dimeric protein (124 kDa), in agreement to the quaternary structure reported for class 1 fumarases 
[7]. To investigate co-factor binding the EPR profiles of TcFHc and TcFHm were assessed (Figure 
1C and D). The resultant spectra contain resonances centered on g~2.019 typical of S=1/2 spin system 
in an axial local symmetry. This pattern type was assigned to [3Fe-4S]+ clusters likely produced by 
the oxidation of [4Fe-4S] clusters [23-26]. [4Fe-4S] clusters are described to be crucial to class I 
fumarases catalytic mechanism where they behave as a Lewis acid that activates the substrates [13, 
14, 23, 27].  Based on their sequence, oligomeric state and co-factor binding, TcFHc and TcFHm 
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clearly show all the characteristics of the class I group of fumarases, distinct from their human 
counterparts.   
 
3.2 Trypanosoma cruzi expresses two functional fumarases  
In other organisms fumarases catalyse the reversible hydration/dehydration of fumarate/malate. To 
determine whether the trypanosomal enzymes could perform these reactions, the ability of purified 
TcFHc and TcFHm to convert fumarate to malate (hydration) and malate to fumarate (dehydration) 
was monitored by following the change in absorbance at 250 nm. Initial assays conducted under 
anaerobic conditions and using fix amount of substrate (1 mM) revealed that both parasite enzymes 
could readily catalyse the above reactions with an optimal pH of 8.0 to 9.0. To study the interaction 
of TcFHc and TcFHm with the two substrates further, assays were then performed in the presence of 
a fixed amount of parasite enzyme (10 µg) using different concentrations of fumarate/malate 
substrates (Table 1). This revealed that TcFHc catalysed the hydration and dehydration reactions 
following the Hill model with a Hill coefficient (h) of 1.4, with its catalytic efficiency (kcat/k0.5
h), 
calculated as suggested in [28], towards the hydration of fumarate: this reaction was six-fold greater 
than the dehydration of malate. In contrast, TcFHm follows the simpler Michaelis-Menten 
mechanism (h = 1) for both reaction directions, displaying a four-fold higher catalytic efficiency for 
malate formation. This indicates that in vitro both TcFHc and TcFHm have a preference for the 
hydration reaction (i.e. fumarate consumption). 
 
3.3 Localization of the T. cruzi fumarases  
  When analysed using PSORTII, TcFHm was predicted to contain an amino terminal sequence with 
potential to target the enzyme to the parasite’s single mitochondrion. To confirm this, versions of 
TcFHm tagged at its carboxyl termini with a 10-amino acid epitope from the human c-myc protein 
(protein designated TcFHm-9e10) or with GFP (designated as TcFHm-GFP) were expressed in T. 
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cruzi epimastigotes. Using parasites expressing TcFHm-9e10, the distribution of the recombinant 
protein was assessed following digitonin permeabilization (Figure 2A). This demonstrated that only 
soluble fractions obtained using the high concentrations of non-ionic detergent required for 
mitochondrial permeabilization were positive for tagged TcFHm. This subcellular location was 
confirmed using T. cruzi expressing TcFHm-GFP where the fluorescence signal was restricted to a 
lattice-like structure found throughout the cell, a pattern typical for trypanosomal proteins localized 
to the large single mitochondrion (Figure 2B). To confirm this, cells were co-stained with the 
mitochondrial dye, MitoTracker. When the images were superimposed, the pattern of colocalization 
indicated that TcFHm-GFP was located in the same compartment as MitoTracker. When the 
fluorescence studies were extended to investigate TcFHc localization, a GFP signal throughout the 
whole cell was observed indicating this fumarase has a cytosolic localization (Figure 2C).  
 
3.4 Functional studies on T. cruzi fumarases  
To investigate the importance of the fumarase repertoire to T. cruzi a reverse genetic approach was 
used. DNA fragments corresponding to the 5′ and 3’ regions of Tcfhc were cloned either side of a 
cassette containing blasticidin or puromycin resistance markers. These were then linearized and 
transfected in T. cruzi epimastigotes to construct heterozyote (Tcfhc+/) and null mutant (TcfhcΔ) 
parasite lines. Southern hybridisation was used to confirm that each integration event had occurred 
and demonstrated that both copies of the full length Tcfhc gene could readily be deleted from the 
parasite genome (Figure 3A and C). As lack of TcFHc had no effect on trypanosome growth and had 
no effect on the trypanosomes ability to infect and grow within mammalian cells (Figure 3F), by 
inference the cytosolic fumarase activity is non-essential for parasite growth under normal culture 
conditions. A similar strategy to interrupt both copies of the Tcfhm gene in the T. cruzi genome was 
employed resulting in construction of a Tcfhm+/- heterozygote and TcfhmΔ null mutants (Figure 3B 
and D). By inference, TcFHm activity is non-essential for epimastigote growth under normal culture 
conditions. Intriguingly, when the growth of insect form epimastigote trypanosomes lacking TcFHm 
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was followed, the parasites failed to grow in the initial 48-h period exhibiting a pronounced lag phase 
(Figure 3E). Additionally, when mammalian cells were infected with T. cruzi TcfhmΔ mutants and 
the parasites cultured as intracellular amastigotes, the trypanosome abundance load per host cell was 
~3-fold lower than wild type (Figure 3F). This indicates that trypanosomes lacking TcFHm are less 
infective than parental parasites or that amastigote growth of the null line inside tissue cultured 
mammalian cell is somehow compromised.  
 
To evaluate whether the combined fumarase activity is essential for parasite viability, attempts to 
interrupt both genes within a single cell to generate a TcfhcΔ TcfhmΔ double null mutant were 
initiated; in these experiments the Tcfhm puromycin-based integration constructs was modified such 
that resistance gene was replaced with sequences encoding for neomycin or hygromycin B 
phosphotransferase.  The neo-containing Tcfhm integration cassette was linearized and transformed 
into T. cruzi TcfhcΔ cells and a Tcfhc null mutant/Tcfhm heterozygote (TcfhcΔ Tcfhm+/-) line selected. 
Southern hybridisation was used to confirm correct integration of each gene disruption event (lane 5 
Figure 3C and D). When the ability of TcfhcΔ Tcfhm+/- line to infect and grow inside mammalian 
cells was monitored, the recombinant parasites behaved similarly to wild type and TcfhcΔ lines 
(Figure 3F). Attempts to generate a TcfhcΔ TcfhmΔ double null mutant line using the hygromycin-
based vector failed, leading us to speculate that the combined TcFHc and TcFHm activity is essential 
for epimastigote growth under normal culture conditions. Unfortunately, rescue experiments could 
not be undertaken as the gene interruption experiments outlined above exhausted all the selectable 
markers available for use in T. cruzi. 
 
3.5 Developing a fumarase inhibitor 
The gene disruption experiments suggest that the total fumarase activity may be essential for parasite 
viability. Encouraged by these observations, we became interested in evaluating this enzyme 
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repertoire as a potential drug target and investigating whether inhibitors specifically targeting class I 
fumarases could be developed. 
 
The mechanism of substrate binding to the iron-sulfur cluster was previously proposed by Flint [23] 
and suggests that both the hydroxyl group of the substrate malate and one oxygen of the closest 
carboxylate are responsible for chelating the labile iron of the 4Fe-4S cluster and allowing the reaction 
to occur (Figure 4A). According to the hard soft (Lewis) acid base theory [29], the iron atoms of the 
cluster act as soft acids known to coordinate to thiol groups which are soft bases. Therefore, the 
chemistry of iron-sulfur clusters suggested to us that the replacement of a hydroxyl group (hard base) 
of L-malate with a thiol, as observed in the thiomalate molecule (Figure 4B), could potentialize the 
binding with the active site iron-sulfur cluster and block the enzyme activity. 
 
To test this hypothesis, parasite fumarase (10 µg) activity was measured in the presence of different 
concentrations of malate (8, 4, 2, 1, and 0.5 mM) and thiomalate (12.86, 4.5, 1.58, 0.55 and 0 µM for 
TcFHc – Figure 4C) and (500, 250, 125, 62.5, 31.25, 15.62, 7.81, 3.91, 1.95, 0.98, 0.49, 0.24, 0.12, 
0.061, 0.015 and 0 µM for TcFHm – Figure 4D). Under the conditions employed, thiomalate 
functioned as a competitive inhibitor of TcFHc and TcFHm dehydration reaction yielding Ki values 
of 4.2 ± 0.5 µM and 4.2 ± 0.5 µM, respectively. Since class II fumarases use an interaction network 
for catalysis that only involves residues and no metal (Figure 5A), we expected thiomalate to be 
selective towards class I fumarases. In fact, thiomalate did not affect the activity of purified class II 
human fumarase (Figure 5B). 
 
When the inhibition studies were extended to investigate other thiol-based compounds, most (BME, 
Cys, GSH, DTT) had no significant effect on TcFHc activity even at high concentrations (>10 mM), 
with only DMSA having an inhibitory effect at concentrations below 2 mM (Figure 4E).  
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4. Discussion 
Fumarases represent a class of metabolic enzymes expressed by many prokaryotic and eukaryotic 
cells where they play key roles in pathways as diverse as the TCA cycle, amino acid metabolism and 
DNA repair [12]. Their importance in humans is manifest when the encoded activity becomes 
compromised such that reduction in fumarase levels can lead to a series of neonatal and infantile 
neurological conditions as well as in promoting certain cancers [30, 31]. Here, we demonstrate that 
T. cruzi expresses two bona fide [4Fe-4S] cluster-containing fumarases that within the parasites 
cytosol or mitochondrion mediate the interconversion of fumarate and malate. Our data also suggest 
that their combined activities is essential for parasite growth, thereby genetically validating this 
enzyme repertoire as a drug target. Thus, the design a molecule to inhibit only the T. cruzi fumarases 
and not the human enzyme may be considered an attractive strategy for the development of new anti-
chagasic compounds. 
 
Based on their sequences, TcFHc and TcFHm display characteristics of the class I fumarases as 
expressed by bacteria and lower eukaryotes, possessing the fumarase (pfam05681) and fumarase C-
terminus (pfam05683) domains that mediate [4Fe-4S] cluster co-factor binding. To confirm these 
computational observations recombinant versions of both enzymes were purified under anaerobic 
conditions following heterologous expression in E.coli and their kinetic properties analyzed. Initial 
assays demonstrated that TcFHc and TcFHm could catalyse the reversible conversion of fumarate 
and malate. As with the related E. coli fumA [23] and aconitase [32], the activity of both parasite 
enzymes was exquisitely sensitive to oxygen with as little as 20 ppm oxygen promoting conversion 
of the [4Fe-4S] to an [3Fe-4S] cluster, with loss of the labile iron leading to their irreversible 
deactivation. More detailed analysis on the kinetic properties of the trypanosomal fumarases revealed 
that whereas TcFHm was shown to exhibit Michaelis-Menten kinetics for both reaction directions 
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over the substrate concentration range tested (Table 1),  TcFHc employed a catalytic mechanism with 
positive cooperativity, in agreement with its dimeric quaternary structure [33]. Since this profile was 
observed for both fumarate and malate, the interference of an optically impure substrate can be ruled 
out considering that fumarate is not a chiral molecule.  
The localization of TcFHc to the cytosol and TcFHm to the mitochondrion as shown 
experimentally is in agreement with in silico predictions using Mitoprot [34] and experimental reports 
for the T. brucei and L. major homologues [15, 35]. However, computation analysis also indicates 
that TcFHc and TcFHm may also be present in glycosomes: glycosomes are modified peroxisomes 
within which several enzymes of the glycolytic pathway are compartmentalized. For TcFHc this 
additional localization, if ever exist, could be due to the presence of the –SKLL sequence at its 
carboxyl terminus, a region that resembles a classical peroxisomal targeting signal 1 (PTS1) (-SKL) 
tripeptide motif. What actually constitutes a PTS1 in glycosomes appears to be less stringent than for 
peroxisomes [36-39]. Although structural studies involving T. brucei PEX5, the receptor that initiates 
protein translocation into the glycosome, in complex with modified PTS1 sequences has revealed that 
the extra leucine added onto the SKL-like tripeptide would occupy an unfavorable highly polar cavity 
which is actually filled by a 1,2-ethanediol molecule what would probably hinder the protein-
transporter interaction [40]. As TcFHc contains this tetrapeptide arrangement at its carboxyl terminal 
it may not be recognized by the glycosomal transport machinery. In the case of TcFHm its amino 
terminal contains a mitochondrial signal peptide (MLRRSAA-) closely followed by an internal 
peroxisomal targeting signal 2 (PTS2) (-KYVPLIPHV-), an arrangement also noted for the  L. major 
and T. brucei orthologs [41]. Using a combination of approaches we clearly show that carboxy 
terminal tagged versions of this fumarase are only present in the parasite’s single mitochondrion and 
at no other sites within the cell. 
 
The endogenous function of each individual T. cruzi fumarase is non-essential to T. cruzi: both 
copies of Tcfhc or Tcfhm could be readily deleted from the genome of epimastigote parasites. For 
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trypanosomes lacking the cytosolic fumarase no obvious phenotype was observed with the 
recombinant parasites growing as insect form epimastigotes, invading mammalian cells as 
trypomastigotes or proliferating as intracellular amastigotes at levels equivalent to controls (Figure 
3F). In contrast, deletion of both Tcfhm gene copies from the T. cruzi genome hampered the parasites 
ability to proliferate in its epimastigote and amastigote forms. As TcFHm most likely participates in 
the Kreb’s cycle lack of its activity may alter the flux of metabolites within this pathway having a 
knock on effect in other biological systems such as in energy production and amino acid biosynthesis. 
Because the mitochondrial enzyme is not essential for parasite growth it is implicit that its activity 
can be complemented possibly indicating that T. cruzi may have the ability to shuttle malate and 
fumarate between cellular compartments [22] (this may also explain why the cytosolic fumarase is 
non-essential) or that the TcFHm deficient cells are able to undergo some type of biochemical 
adaptation and metabolic reprogramming, analogous to leiomyomatosis renal carcinoma cells that are 
null for fumarase [42].  
 
The importance of the total fumarase activity to T. cruzi became evident when attempts were made 
to generate parasites lacking both genes. Here, three out of four fumarase gene alleles could readily 
be disrupted in epimastigote form trypanosomes with failure to interrupt the final gene strongly 
suggesting that the total fumarase activity is essential for parasite viability. Addition of malate or 
fumarate to the medium, a technique used to rescue for the fumarase knockdown phenotype in T. 
brucei [15], failed to generate the desired TcfhcΔ TcfhmΔ lines. The inability to complement for 
fumarase activity deficiency through supplementation of the medium with exogenous dicarboxylate 
indicates that T. cruzi epimastigotes may lack fumarate and malate transporters that facilitate their 
uptake into the cell. 
 
Based on their biochemical features and apparent essential activity the T. cruzi fumarase repertoire 
possess many hallmarks required in a druggable target. To further assess whether these enzymes fulfil 
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other criterion required for chemotherapeutic development, an assay for specific class I fumarases 
inhibitors was undertaken with thiomalate, a chemical rationally selected based on its similarity to 
the malate/fumarate substrates and low toxicity to humans [43]. Assays revealed that this structure 
could readily inhibit the trypanosomal fumarase activity without significantly affecting the human 
enzyme via a mechanism postulated to involve thiomalate selectively binding to the iron-sulfur 
cluster, a co-factor absent from HsFH [44] (Figure 4A). Thiomalate therefore represents a novel 
chemical lead that because of its low lipophilicity will require derivatization in order to develop more 
bioavailable variants that can be used against intracellular pathogens such as T. cruzi.  
 
Our work has demonstrated that the T. cruzi fumarase complement should be investigated as a 
potential druggable anti-chagasic target and has resulted in the identification of a lead structure in the 
form of thiomalate. As several other medically important protozoan parasites including Plasmodium 
falciparum, Cryptosporidium and Leishmania also express class I fumarases then the work reported 
here may facilitate the development of novel strategies towards the development of new treatments 
for a range of globally important pathogens. 
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TABLE 
Table 1. Kinetic parameters of T. cruzi fumarases. TcFHc and TcFHm kinetic parameters were obtained 
for the L-malate and fumarate substrates under anaerobic conditions. Initial rates were plotted versus 
substrate concentration and the data fitted to Hill model. Enzyme concentration was determined by 
absorbance of [4Fe-4S] cluster at 410 nm (ε410nm=15000 M
-1.cm-1).  is the enzyme turnover number,  
is the Hill coefficient, . is the substrate concentration at half maximum velocity when  	 1,   is the 
substrate concentration at half maximum velocity when   1, /.
  and /  are the enzyme 
catalytic efficiencies for a given substrate and  is the adjusted coefficient of determination. 
 
 
 
 
 
  
  
FIGURE LEGENDS 
 
FIGURE 1. Analysis of purified trypanosomal fumarases. A). Purified TcFHc (lane 1), TcFHm (lane 2) 
(upper band corresponding to unprocessed SUMO tag) and HsFH (lane 3) (1 µg per enzyme) were 
fractionated by SDS-PAGE. B). Elution profile of DTT (1 mM) treated TcFHc off a Superdex 300 column. 
C and D). EPR spectra of T. cruzi fumarases TcFHc (C) and TcFHm (D). Both spectra contain resonances 
centered in g ~ 2.019 which is considered a fingerprint of a [3Fe-4S]+ cluster. This type of cluster in class 
I fumarases are generated after the oxidation of [4Fe-4S] cluster by oxygen. 
 
FIGURE 2. Subcellular localization of T. cruzi fumarases: A). Digitonin permeabilization of T. cruzi 
cells expressing c-myc tagged TcFHm: TcFHm was released concomitantly with ASCT (mitochondrial 
marker) at high digitonin concentration, while the enzymes aldolase (glycosomal) and enolase (cytosolic) 
were released at lower digitonin concentrations. B and C). T. cruzi expressing GFP tagged TcFHm (B) or 
TcFHc (C) co-stained with DAPI (DNA) and/or Mitotracker (MT) were analyzed by confocal microscopy. 
The pattern of TcFHm-GFP and Mitotracker co-localization (yellow) is shown in the merged image 
indicating this trypanosomal enzyme is present in the parasites’ single mitochondrion. For TcFHc-GFP, a 
signal throughout the whole cell was observed typical of cytosolic proteins.  
 
FIGURE 3. Analysis of T. cruzi fumarases null mutant lines. A and B). Diagrams of the Tcfhc (A) and 
Tcfhm (B) alleles (both in light grey) and the effects of gene disruption. The fumarase encoding genes were 
interrupted using cassettes containing the puromycin (pac), blasticidin (bla) or neomycin (neo) selectable 
markers (dark grey) flanked by tubulin intergenic elements (hashed boxes) required for processing of 
mRNA. The dotted lines correspond to probes used to check integration. The position of the predicted NcoI 
(N) or XhoI (X) sites plus the band sizes (in kbp) obtained after hybridization are shown. C and D). 
Autoradiograph of NcoI- (C) or XhoI- (D) digested genomic DNA from T. cruzi Sylvio X10.6 wild type 
  
(lane 1), Tcfhc+/-BLA or Tcfhm+/-BLA heterozygote (lane 2), Tcfhc+/-PAC or Tcfhm+/-PAC heterozygote (lane 3), 
Tcfhc∆ or Tcfhm∆ null mutant (lane 4) and Tcfhc∆ null mutant/Tcfhm+/-NEO heterozygote (lane 5) cell lines 
hybridized with labelled Tcfhc (panel C) or Tcfhm (panel D). The band sizes are in kbp. E). The growth of 
T. cruzi Sylvio X10.6 wild type (WT) (blue continuous line) and Tcfhm∆ null mutant (red dotted line) cells 
was monitored over a 20 day period. Each data point represents a mean ± standard deviation from cell 
counts performed on three independent cultures. F). T. cruzi Sylvio X10.6 wild type (WT), Tcfhc∆ or 
Tcfhm∆ null mutants and Tcfhc∆null mutant/Tcfhm+/-NEO heterozygote lines were used to infect mammalian 
(Vero) cells. The number of infected cells and the number of amastigotes per mammalian cell were 
determined and the mean abundance of parasites per mammalian cell. Error bars represent the 95% 
confidence intervals calculated using the quantitative parasitology software QPweb 1.0. The figure to the 
left shows a mammalian cell infected with wild type T. cruzi Sylvio X10/6. 
 
FIGURE 4. Inhibitor design for class I fumarase. A) The structure of aconitase in complex with isocitrate 
(PDB ID: 7ACN) was used as a guide for modeling the binding of malate to the iron sulfur cluster first 
proposed by Flint [45]. B) We hypothesized that replacing the hydroxyl group of malate by a thiol group 
would result in a strong interaction with the cluster, therefore inhibiting the enzyme. C) TcFHc activity was 
evaluated in the presence of different thiomalate concentrations. The data fitted a competitive inhibition 
model with Ki = 4.2 ± 0.5 µM. D) Inhibition of TcFHm by thiomalate was assessed and the data fitted a 
competive model   E) The effect of various thiol containing compounds on TcFHc activity was assessed. 
β-mercaptoethanol (BME), cysteine (Cys), reduced glutathione (GSH) and dithiotreitol (DTT) only 
inhibited TcFHc when their concentrations were higher than that of L-malate concentration used (8 mM). 
Only meso-2,3-dimercaptosuccinate (DMSA) inhibited TcFHc activity suggesting that this molecule 
resembles the substrate to access the active site of class I fumarases.   
 
 
 
  
 
FIGURE 5. Thiomalate is selective towards the parasite fumarase. A) The structures of the human 
fumarase (PDB ID: 3E04, green) and Micobacterium tuberculosis fumarase in complex with fumarate 
(PDB ID: 4APB, cyan) were superimposed to show that the binding of fumarate to class II fumarases relies 
only on residue interactions and is independent of iron. B) Thiomalate was also tested against HsFH activity 
and inhibition only occurred when the concentrations of inhibitor and substrate were similar, which means 
thiomalate is a poor inhibitor for the human fumarase.  
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